TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT07447817: Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With Cytopenias

Sponsor: John Mascarenhas · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 26 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$759,000

Rescue Site Savings

+$517,500

Unlock Full NCT07447817 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07447817 Rescue Dossier →